A Phase 1 interventional study of Tenofovir alafenamide/emtricitabine and GSK3640254 in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-21.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing tenofovir alafenamide in HIV Infections — 4 open to participants now, 6 under way, 3 of them phase 3. tenofovir alafenamide · HIV Infections.
Among the 23 studies testing tenofovir alafenamide in HIV Infections, this one is the 23rd largest by enrollment, is the only one that started in 2019, is the only one in phase 1, and was the 14th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →4 of the 23 studies testing tenofovir alafenamide in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
CAN Community Health · Sites in United States
Ages 18+
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+ · Men only
University College, London
Ages 4 wk–14 yrs
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 10 · Phase 4 8
First in 2002; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 133 across the 23 interventional studies. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 189th largest by enrollment of the 210 interventional ones that give a count, is one of 14 that started in 2019, is one of 83 in phase 1, and was the 198th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing tenofovir alafenamide in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07476339CAN Community HealthREINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE | 2027-06-17 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing tenofovir alafenamide in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
Human immunodeficiency virus (HIV) infection frequently involves combination drug therapy for its treatment; hence, it is important to understand their interactions and resulting changes in exposure which are associated with medications. This is a Phase-1, open-label, fixed-sequence 2-period, one-way drug interaction study to assess the pharmacokinetic (PK), safety, and tolerability of GSK3640254 and Tenofovir alafenamide/emtricitabine (TAF/FTC) when administered alone and in combination in healthy subjects. The study will consist of a screening period of 28 days before the first dose of study intervention followed by 2 sequential treatment periods. Subjects will be administered TAF/FTC 25/200 milligram (mg) once daily (QD) on Days 1 to 14 of Period 1 followed by co-administration of TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 to 7 of Period 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
Drug: Tenofovir alafenamide/emtricitabine · Drug: GSK3640254
Drug pages: Tenofovir alafenamide · Emtricitabine
TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of TAF
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Parameter Population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: AUC (0-tau) of TAF
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: Maximum Observed Concentration (Cmax) of TAF
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: Cmax of TAF
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: AUC (0-tau) of FTC
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: AUC (0-tau) of FTC
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1:Cmax of FTC
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2:Cmax of FTC
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of FTC
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: Ctau of FTC
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: AUC (0-tau) of Tenofovir (TFV)
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: AUC (0-tau) of TFV
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: Cmax of TFV
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: Cmax of TFV
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: Ctau of TFV
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: Ctau of TFV
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAE)
An adverse events (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before
Time frame: Up to Day 24
Period 1: Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, and 14
Period 2: Change From Baseline in Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
Blood samples were collected at indicated timepoints for analysis for hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of the Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, and 14
Period 2: Absolute Values of the Hematology Parameter of Platelet Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Hematology Parameter of Hematocrit
Blood samples were collected at indicated timepoints for analysis of hematology parameter like hematocrit. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Hematology Parameter of Hematocrit
Blood samples were collected at indicated time-points for analysis for hematology parameter like hematocrit. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of the Hematology Parameter: Hematocrit
Blood samples were collected at indicated time points for analysis for hematology parameter like hematocrit. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of the Hematology Parameter: Hematocrit
Blood samples were collected at indicated time-points for analysis for hematology parameter like hematocrit. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Hematology Parameter of Hemoglobin
Blood samples were collected at indicated timepoints for analysis for hematology parameter like hemoglobin. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Hematology Parameter of Hemoglobin
Blood samples were collected at indicated timepoints for analysis of hematology parameter like hemoglobin. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of the Hematology Parameter: Hemoglobin
Blood samples were collected at indicated time-points for analysis for hematology parameter like hemoglobin. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of the Hematology Parameter: Hemoglobin
Blood samples were collected at indicated time-points for analysis for hematology parameter like hemoglobin. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Hematology Parameter of Mean Corpuscle Hemoglobin (MCH)
Blood samples were collected at indicated timepoints for analysis of hematology parameter like MCH. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Hematology Parameter of MCH
Blood samples were collected at indicated timepoints for analysis for hematology parameter like MCH. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of the Hematology Parameter: MCH
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCH. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of the Hematology Parameter: MCH
Blood samples were collected at indicated time-points for analysis of hematology parameter like MCH. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Hematology Parameter of Mean Corpuscle Volume (MCV)
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Hematology Parameter of MCV
Blood samples were collected at indicated timepoints for analysis for hematology parameter like MCV. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of the Hematology Parameter: MCV
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of the Hematology Parameter: MCV
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Hematology Parameter of Erythrocytes
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Hematology Parameter of Erythrocytes
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of the Hematology Parameter: Erythrocytes
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of the Hematology Parameter: Erythrocytes
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN), Carbon Dioxide (CO2), Chloride and Phosphorus
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
Blood samples were collected at indicated time-points for analysis of clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of Clinical Chemistry Parameter of Glucose, Anion Gap, Cholesterol, Calcium, Potassium, Sodium, BUN, CO2, Chloride and Phosphorus
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Clinical Chemistry Parameter of Alkaline Phosphatase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactate Dehydrogenase (LDH), Gamma-glutamyl Transferase (GGT), and Creatine Phosphokinase (CK)
Blood samples were collected at indicated time-points for analysis of clinical chemistry parameter like alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of Clinical Chemistry Parameter of Alkaline Phosphatase, ALT, AST, LDH, GGT, and CK
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Clinical Chemistry Parameter of Lipase and Amylase
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Clinical Chemistry Parameter of Lipase and Amylase
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of Chemistry Parameters of Lipase and Amylase
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of Chemistry Parameters of Lipase and Amylase
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of Clinical Chemistry Parameter of Total Bilirubin, Direct Bilirubin, and Creatinine
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, creatinine and uric acid. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of of total protein, albumin and globulin. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total protein, albumin and globulin. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total protein, albumin and globulin. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of Clinical Chemistry Parameter of Total Protein, Albumin and Globulin
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, creatinine and uric acid. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Specific Gravity of Urine
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Specific Gravity of Urine
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of Specific Gravity of Urine
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of Specific Gravity of Urine
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Potential of Hydrogen (pH) of Urine
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in pH of Urine
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of pH of Urine
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of pH of Urine
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Urine Urobilinogen
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 7, 14
Period 2: Change From Baseline in Urine Urobilinogen
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Absolute Values of Urine Urobilinogen
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1.
Time frame: Baseline and at Days 7, 14
Period 2: Absolute Values of Urine Urobilinogen
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Period 1 Day 14 for Period 2.
Time frame: Baseline and at Days 3, 7, 9
Period 1: Change From Baseline in Heart Rate
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Day 1, 2 and 4 hours post-dose
Period 2: Change From Baseline in Heart Rate
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose
Period 1: Absolute Values of Heart Rate
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Day 1, 2 and 4 hours post-dose
Period 2: Absolute Values of Heart Rate
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose
Period 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, Fridericia QT Correction Formula (QTcF) Interval, and Bazett QT Correction Formula (QTcB) Interval
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interal, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Day 1, 2 and 4 hours post-dose
Period 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interal, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose
Period 1: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Day 1, 2 and 4 hours post-dose
Period 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval, and QTcB Interval
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Day 1, 2 and 4 hours post-dose; Day 4, Pre-dose, 2 and 4 hours post-dose; Day 7, Pre-dose, 2 and 4 hours post-dose; Day 9 post-dose
Period 1: Change From Baseline in Temperature
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 2, 3, 4, 5 and 7
Period 2: Change From Baseline in Temperature
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 4, 7, 9, and 10
Period 1: Absolute Values of Temperature
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Days 2, 3, 4, 5 and 7
Period 2: Absolute Values of Temperature
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Days 4, 7, 9, and 10
Period 1: Change From Baseline in Pulse Rate
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 2, 3, 4, 5 and 7
Period 2: Change From Baseline in Pulse Rate
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 4, 7, 9, and 10
Period 1: Absolute Values of Pulse Rate
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Days 2, 3, 4, 5 and 7
Period 2: Absolute Values of Pulse Rate
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Days 4, 7, 9, and 10
Period 1: Change From Baseline in Respiratory Rate
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 2, 3, 4, 5 and 7
Period 2: Change From Baseline in Respiratory Rate
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 4, 7, 9, and 10
Period 1: Absolute Values of Respiratory Rate
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Days 2, 3, 4, 5 and 7
Period 2: Absolute Values of Respiratory Rate
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Days 4, 7, 9, and 10
Period 1: Change From Baseline in Blood Pressure
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 2, 3, 4, 5 and 7
Period 2: Change From Baseline in Blood Pressure
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Days 4, 7, 9, and 10
Period 1: Absolute Values of Blood Pressure
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Days 2, 3, 4, 5 and 7
Period 2: Absolute Values of Blood Pressure
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
Time frame: Baseline and at Days 4, 7, 9, and 10
Period 2: AUC (0-tau) of GSK3640254
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 2: Cmax of GSK3640254
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 2: Ctau of GSK3640254
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 1 and 2 hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 1 and 2hours, 2 hours 30 minutes, 3 and 3 hour 30 minutes, 4 and 4 hour 30 minutes, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: Tmax of TAF
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: Tmax of TAF
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: Tmax of FTC
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: Tmax of FTC
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
Period 1: Tmax of TFV
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 1 Day 14
Period 2: Tmax of TFV
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
Time frame: Pre-dose, 15, 30, 45 minutes, 1 hour, 1 hour 30 minutes, 2, 3, 4, 5, 6, 8, 12 and 24 hours in Period 2 Day 7
This was an open-label, single-sequence one-way interaction drug interaction study to investigate the effect of GSK3640254 on the pharmacokinetics (PK) of tenofovir alafenamide (TAF) and emtricitabine (FTC).
| Milestone | TAF/FTC Followed by TAF/FTC+GSK3640254 |
|---|---|
| Started | 16 |
| Completed | 16 |
| Not completed | 0 |
| Milestone | TAF/FTC Followed by TAF/FTC+GSK3640254 |
|---|---|
| Started | 16 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). Pharmacokinetic (PK) parameters were calculated by standard non-compartmental analysis. PK Parameter Population included all participants who underwent plasma PK sampling and had evaluable PK parameters estimated.
| Hours*nanogram per milliliter | TAF/FTC |
|---|---|
| Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of TAF | 250.4 ± 58.2 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
| Hours*nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: AUC (0-tau) of TAF | 215.4 ± 36.3 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC |
|---|---|
| Period 1: Maximum Observed Concentration (Cmax) of TAF | 203.4 ± 56.1 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Cmax of TAF | 175.1 ± 44.4 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
| Hours*nanogram per milliliter | TAF/FTC |
|---|---|
| Period 1: AUC (0-tau) of FTC | 9787.5 ± 15.5 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
| Hours*nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: AUC (0-tau) of FTC | 9421.0 ± 14.4 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC |
|---|---|
| Period 1:Cmax of FTC | 1811 ± 15.9 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2:Cmax of FTC | 1701 ± 20.9 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC |
|---|---|
| Period 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of FTC | 71.81 ± 25.5 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Ctau of FTC | 82.92 ± 29.1 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
| Hours*nanogram per milliliter | TAF/FTC |
|---|---|
| Period 1: AUC (0-tau) of Tenofovir (TFV) | 221.9 ± 18.3 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
| Hours*nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: AUC (0-tau) of TFV | 229.1 ± 21.5 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC |
|---|---|
| Period 1: Cmax of TFV | 13.14 ± 17.8 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Cmax of TFV | 13.30 ± 20.8 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC |
|---|---|
| Period 1: Ctau of TFV | 7.688 ± 20.4 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Ctau of TFV | 8.244 ± 22.9 |
An adverse events (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before
| Participants | TAF/FTC | TAF/FTC+GSK3640254 |
|---|---|---|
| Non-SAEs | 9 | 3 |
| SAEs | 0 | 0 |
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Giga cells per liter | TAF/FTC |
|---|---|
| Basophils, Period 1 Day 7 | -0.005 ± 0.0167 |
| Basophils, Period 1 Day 14 | -0.006 ± 0.0260 |
| Eosinophils, Period 1 Day 7 | -0.021 ± 0.0795 |
| Eosinophils, Period 1 Day 14 | -0.020 ± 0.1531 |
| Monocytes, Period 1 Day 7 | 0.014 ± 0.1808 |
| Monocytes, Period 1 Day 14 | 0.049 ± 0.2718 |
| Leukocytes, Period 1 Day 7 | -0.08 ± 1.795 |
| Leukocytes, Period 1 Day 14 | 0.27 ± 2.191 |
| Lymphocytes, Period 1 Day 7 | -0.246 ± 0.3089 |
| Lymphocytes, Period 1 Day 14 | -0.262 ± 0.4138 |
| Neutrophils, Period 1 Day 7 | 0.188 ± 1.5473 |
| Neutrophils, Period 1 Day 14 | 0.513 ± 1.7986 |
| Platelets, Period 1 Day 7 | 3.3 ± 21.23 |
| Platelets, Period 1 Day 14 | 21.8 ± 35.37 |
Blood samples were collected at indicated timepoints for analysis for hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Giga cells per liter | TAF/FTC+GSK3640254 |
|---|---|
| Basophils, Period 2 Day 3, n= 15 | -0.004 ± 0.0196 |
| Basophils, Period 2 Day 7, n= 15 | -0.002 ± 0.0204 |
| Basophils, Period 2 Day 9, n= 15 | 0.003 ± 0.0150 |
| Eosinophils, Period 2 Day 3, n=15 | -0.023 ± 0.0811 |
| Eosinophils, Period 2 Day 7, n=15 | -0.039 ± 0.1058 |
| Eosinophils, Period 2 Day 9, n=16 | -0.043 ± 0.1093 |
| Monocytes, Period 2 Day 3, n= 16 | -0.053 ± 0.1895 |
| Monocytes, Period 2 Day 7, n= 15 | -0.077 ± 0.1709 |
| Monocytes, Period 2 Day 9, n= 15 | -0.104 ± 0.1672 |
| Leukocytes, Period 2 Day 3, n= 16 | -1.06 ± 1.188 |
| Leukocytes, Period 2 Day 7, n= 15 | -0.61 ± 1.050 |
| Leukocytes, Period 2 Day 9, n= 15 | -0.49 ± 1.193 |
| Lymphocytes, Period 2 Day 3, n= 16 | -0.158 ± 0.2296 |
| Lymphocytes, Period 2 Day 7, n= 15 | -0.105 ± 0.2306 |
| Lymphocytes, Period 2 Day 9, n= 15 | -0.111 ± 0.2728 |
| Neutrophils, Period 2 Day 3, n= 16 | -0.868 ± 0.9597 |
| Neutrophils, Period 2 Day 7, n= 15 | -0.417 ± 0.9069 |
| Neutrophils, Period 2 Day 9, n= 15 | -0.282 ± 1.0161 |
| Platelets, Period 2 Day 3, n= 16 | 9.2 ± 20.41 |
| Platelets, Period 2 Day 7, n= 15 | 19.8 ± 43.02 |
| Platelets, Period 2 Day 9, n= 15 | 16.2 ± 38.11 |
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Day -1 for Period 1.
| Giga cells per liter | TAF/FTC |
|---|---|
| Basophils, Period 1 Baseline | 0.046 ± 0.0216 |
| Basophils, Period 1 Day 7 | 0.041 ± 0.0189 |
| Basophils, Period 1 Day 14 | 0.040 ± 0.0256 |
| Eosinophils, Period 1 Baseline | 0.225 ± 0.1918 |
| Eosinophils, Period 1 Day 7 | 0.204 ± 0.1737 |
| Eosinophils, Period 1 Day 14 | 0.205 ± 0.1766 |
| Monocytes, Period 1 Baseline | 0.522 ± 0.1147 |
| Monocytes, Period 1 Day 7 | 0.536 ± 0.2063 |
| Monocytes, Period 1 Day 14 | 0.571 ± 0.2830 |
| Leukocytes, Period 1 Baseline | 6.18 ± 1.336 |
| Leukocytes, Period 1 Day 7 | 6.10 ± 2.024 |
| Leukocytes, Period 1 Day 14 | 6.45 ± 2.231 |
| Lymphocytes, Period 1 Baseline | 1.945 ± 0.7419 |
| Lymphocytes, Period 1 Day 7 | 1.699 ± 0.5822 |
| Lymphocytes, Period 1 Day 14 | 1.683 ± 0.4988 |
| Neutrophils, Period 1 Baseline | 3.441 ± 0.9719 |
| Neutrophils, Period 1 Day 7 | 3.628 ± 1.9503 |
| Neutrophils, Period 1 Day 14 | 3.954 ± 1.9141 |
| Platelets, Period 1 Baseline | 253.3 ± 49.81 |
| Platelets, Period 1 Day 7 | 256.6 ± 49.72 |
| Platelets, Period 1 Day 14 | 275.1 ± 53.39 |
Blood samples were collected at indicated timepoints for analysis of hematology parameters like platelet count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was defined as Period 1 Day 14 for Period 2.
| Giga cells per liter | TAF/FTC+GSK3640254 |
|---|---|
| Basophils, Period 2 Baseline, n= 16 | 0.040 ± 0.0256 |
| Basophils, Period 2 Day 3, n= 15 | 0.036 ± 0.0182 |
| Basophils, Period 2 Day 7, n= 15 | 0.038 ± 0.0152 |
| Basophils, Period 2 Day 9, n= 15 | 0.043 ± 0.0232 |
| Eosinophils, Period 2 Baseline, n= 16 | 0.208 ± 0.1764 |
| Eosinophils, Period 2 Day 3, n= 15 | 0.185 ± 0.1533 |
| Eosinophils, Period 2 Day 7, n= 15 | 0.157 ± 0.1405 |
| Eosinophils, Period 2 Day 9, n= 16 | 0.153 ± 0.1384 |
| Monocytes, Period 2 Baseline, n= 16 | 0.545 ± 0.2127 |
| Monocytes, Period 2 Day 3, n= 16 | 0.492 ± 0.1975 |
| Monocytes, Period 2 Day 7, n= 15 | 0.448 ± 0.1472 |
| Monocytes, Period 2 Day 9, n= 15 | 0.421 ± 0.1212 |
| Leukocytes, Period 2 Baseline, n= 16 | 6.20 ± 1.752 |
| Leukocytes, Period 2 Day 3, n= 16 | 5.14 ± 1.035 |
| Leukocytes, Period 2 Day 7, n= 15 | 5.39 ± 1.311 |
| Leukocytes, Period 2 Day 9, n= 15 | 5.51 ± 1.415 |
| Lymphocytes, Period 2 Baseline, n= 16 | 1.718 ± 0.4814 |
| Lymphocytes, Period 2 Day 3, n= 16 | 1.560 ± 0.3786 |
| Lymphocytes, Period 2 Day 7, n= 15 | 1.570 ± 0.4116 |
| Lymphocytes, Period 2 Day 9, n= 15 | 1.563 ± 0.4236 |
| Neutrophils, Period 2 Baseline, n= 16 | 3.724 ± 1.3787 |
| Neutrophils, Period 2 Day 3, n= 16 | 2.857 ± 0.8106 |
| Neutrophils, Period 2 Day 7, n= 15 | 3.189 ± 1.0515 |
| Neutrophils, Period 2 Day 9, n= 15 | 3.324 ± 1.1988 |
| Platelets, Period 2 Baseline, n= 16 | 274.3 ± 51.10 |
| Platelets, Period 2 Day 3, n= 16 | 283.4 ± 54.62 |
| Platelets, Period 2 Day 7, n= 15 | 294.0 ± 54.62 |
| Platelets, Period 2 Day 9, n= 15 | 290.4 ± 73.92 |
Blood samples were collected at indicated timepoints for analysis of hematology parameter like hematocrit. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Proportion of red blood cells in blood | TAF/FTC |
|---|---|
| Day 7 | 0.0121 ± 0.01389 |
| Day 14 | 0.0189 ± 0.01304 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like hematocrit. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Proportion of red blood cells in blood | TAF/FTC+GSK3640254 |
|---|---|
| Day 3, n= 16 | -0.0147 ± 0.00982 |
| Day 7, n= 15 | -0.0007 ± 0.01369 |
| Day 9, n= 15 | -0.0204 ± 0.01371 |
Blood samples were collected at indicated time points for analysis for hematology parameter like hematocrit. Baseline was defined as Day -1 for Period 1.
| Proportion of red blood cells in blood | TAF/FTC |
|---|---|
| Baseline | 0.4264 ± 0.01891 |
| Day 7 | 0.4384 ± 0.02358 |
| Day 14 | 0.4453 ± 0.01997 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like hematocrit. Baseline was defined as Period 1 Day 14 for Period 2.
| Proportion of red blood cells in blood | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 0.4453 ± 0.01997 |
| Day 3, n= 16 | 0.4306 ± 0.01780 |
| Day 7, n= 15 | 0.4444 ± 0.02234 |
| Day 9, n= 15 | 0.4247 ± 0.01518 |
Blood samples were collected at indicated timepoints for analysis for hematology parameter like hemoglobin. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Grams per liter | TAF/FTC |
|---|---|
| Day 7 | 6.1 ± 4.51 |
| Day 14 | 8.4 ± 3.98 |
Blood samples were collected at indicated timepoints for analysis of hematology parameter like hemoglobin. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Grams per liter | TAF/FTC+GSK3640254 |
|---|---|
| Day 3, n= 16 | -3.9 ± 3.51 |
| Day 7, n= 15 | -1.1 ± 4.58 |
| Day 9, n= 15 | -6.4 ± 5.55 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like hemoglobin. Baseline was defined as Day -1 for Period 1.
| Grams per liter | TAF/FTC |
|---|---|
| Baseline | 142.0 ± 6.70 |
| Day 7 | 148.1 ± 8.11 |
| Day 14 | 150.4 ± 7.45 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like hemoglobin. Baseline was defined as Period 1 Day 14 for Period 2.
| Grams per liter | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 150.4 ± 7.45 |
| Day 3, n= 16 | 146.4 ± 6.37 |
| Day 7, n= 15 | 149.1 ± 7.26 |
| Day 9, n= 15 | 143.9 ± 5.19 |
Blood samples were collected at indicated timepoints for analysis of hematology parameter like MCH. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Picograms | TAF/FTC |
|---|---|
| Day 7 | 0.13 ± 0.272 |
| Day 14 | 0.36 ± 0.276 |
Blood samples were collected at indicated timepoints for analysis for hematology parameter like MCH. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Picograms | TAF/FTC+GSK3640254 |
|---|---|
| Day 3, n= 16 | -0.11 ± 0.205 |
| Day 7, n= 15 | -0.21 ± 0.203 |
| Day 9, n= 15 | -0.17 ± 0.253 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCH. Baseline was defined as Day -1 for Period 1.
| Picograms | TAF/FTC |
|---|---|
| Baseline | 28.63 ± 1.780 |
| Day 7 | 28.75 ± 1.687 |
| Day 14 | 28.98 ± 1.690 |
Blood samples were collected at indicated time-points for analysis of hematology parameter like MCH. Baseline was defined as Period 1 Day 14 for Period 2.
| Picograms | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 28.98 ± 1.690 |
| Day 3, n= 16 | 28.88 ± 1.699 |
| Day 7, n= 15 | 28.83 ± 1.630 |
| Day 9, n= 15 | 28.87 ± 1.702 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Femtoliters | TAF/FTC |
|---|---|
| Day 7 | -0.83 ± 0.620 |
| Day 14 | -0.07 ± 0.712 |
Blood samples were collected at indicated timepoints for analysis for hematology parameter like MCV. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Femtoliters | TAF/FTC+GSK3640254 |
|---|---|
| Day 3, n= 16 | -1.02 ± 0.483 |
| Day 7, n= 15 | -0.17 ± 0.472 |
| Day 9, n= 15 | -0.82 ± 0.499 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Day -1 for Period 1.
| Femtoliters | TAF/FTC |
|---|---|
| Baseline | 85.92 ± 4.690 |
| Day 7 | 85.09 ± 4.504 |
| Day 14 | 85.85 ± 4.492 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like MCV. Baseline was defined as Period 1 Day 14 for Period 2.
| Femtoliters | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 85.85 ± 4.492 |
| Day 3, n= 16 | 84.83 ± 4.490 |
| Day 7, n= 15 | 85.85 ± 4.491 |
| Day 9, n= 15 | 85.20 ± 4.601 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Trillion cells per liter | TAF/FTC |
|---|---|
| Day 7 | 0.189 ± 0.1485 |
| Day 14 | 0.226 ± 0.1360 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Trillion cells per liter | TAF/FTC+GSK3640254 |
|---|---|
| Day 3, n= 16 | -0.113 ± 0.1123 |
| Day 7, n= 15 | 0.000 ± 0.1466 |
| Day 9, n= 15 | -0.189 ± 0.1697 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Day -1 for Period 1.
| Trillion cells per liter | TAF/FTC |
|---|---|
| Baseline | 4.977 ± 0.3351 |
| Day 7 | 5.166 ± 0.3679 |
| Day 14 | 5.203 ± 0.3604 |
Blood samples were collected at indicated time-points for analysis for hematology parameter like erythrocytes. Baseline was defined as Period 1 Day 14 for Period 2.
| Trillion cells per liter | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 5.203 ± 0.3604 |
| Day 3, n= 16 | 5.090 ± 0.3395 |
| Day 7, n= 15 | 5.190 ± 0.4087 |
| Day 9, n= 15 | 5.001 ± 0.3446 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Millimoles per Liter | TAF/FTC |
|---|---|
| Glucose, Day 7 | -0.160 ± 0.3793 |
| Glucose, Day 14 | -0.320 ± 0.3432 |
| Cholesterol, Day 7 | -0.004 ± 0.3735 |
| Cholesterol, Day 14 | -0.389 ± 0.3533 |
| Anion gap, Day 7 | 1.9 ± 2.08 |
| Anion gap, Day 14 | 2.2 ± 1.42 |
| Calcium, Day 7 | 0.028 ± 0.0780 |
| Calcium, Day 14 | 0.028 ± 0.0556 |
| CO2, Day 7 | -1.6 ± 1.93 |
| CO2, Day 14 | -0.9 ± 1.20 |
| Chloride, Day 7 | -1.1 ± 1.06 |
| Chloride, Day 14 | -2.0 ± 1.46 |
| Phosphate, Day 7 | 0.017 ± 0.0960 |
| Phosphate, Day 14 | 0.026 ± 0.1330 |
| Potassium, Day 7 | 0.03 ± 0.304 |
| Potassium, Day 14 | -0.03 ± 0.328 |
| Sodium, Day 7 | -0.6 ± 1.45 |
| Sodium, Day 14 | -0.6 ± 1.59 |
| Triglycerides, Day 7 | 0.092 ± 0.4841 |
| Triglycerides, Day 14 | -0.044 ± 0.4569 |
| BUN, Day 7 | -0.018 ± 1.2157 |
| BUN, Day 14 | -0.195 ± 1.0640 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Millimoles per Liter | TAF/FTC+GSK3640254 |
|---|---|
| Glucose, Day 3, n= 15 | 0.236 ± 0.2463 |
| Glucose, Day 7, n= 15 | 0.315 ± 0.3282 |
| Glucose, Day 9, n= 15 | 0.136 ± 0.2433 |
| Cholesterol, Day 3, n=15 | 0.011 ± 0.2372 |
| Cholesterol, Day 7, n= 15 | 0.102 ± 0.3899 |
| Cholesterol, Day 9, n= 16 | 0.030 ± 0.4594 |
| Anion gap, Day 3, n= 16 | -0.4 ± 1.82 |
| Anion gap, Day 7, n= 15 | -0.5 ± 1.73 |
| Anion gap, Day 9, n= 15 | -0.3 ± 1.67 |
| Calcium, Day 3, n= 16 | 0.013 ± 0.0478 |
| Calcium, Day 7, n= 15 | 0.037 ± 0.0568 |
| Calcium, Day 9, n= 15 | 0.033 ± 0.0628 |
| CO2, Day 3, n= 16 | -0.5 ± 1.26 |
| CO2, Day 7, n= 15 | -0.1 ± 1.36 |
| CO2, Day 9, n= 15 | -0.4 ± 1.18 |
| Chloride, Day 3, n= 16 | 2.3 ± 1.20 |
| Chloride, Day 7, n= 15 | 0.6 ± 1.35 |
| Chloride, Day 9, n= 15 | 1.3 ± 1.72 |
| Phosphate, Day 3, n= 16 | 0.062 ± 0.0683 |
| Phosphate, Day 7, n= 15 | 0.002 ± 0.0800 |
| Phosphate, Day 9, n= 15 | 0.007 ± 0.0584 |
| Potassium, Day 3, n= 16 | 0.01 ± 0.284 |
| Potassium, Day 7, n= 15 | -0.03 ± 0.213 |
| Potassium, Day 9, n= 15 | 0.10 ± 0.344 |
| Sodium, Day 3, n= 16 | 1.4 ± 1.36 |
| Sodium, Day 7, n= 15 | 0.1 ± 1.53 |
| Sodium, Day 9, n= 15 | 0.6 ± 1.06 |
| Triglycerides, Day 3, n= 16 | -0.003 ± 0.1753 |
| Triglycerides, Day 7, n= 15 | 0.111 ± 0.2414 |
| Triglycerides, Day 9, n= 15 | -0.049 ± 0.2747 |
| BUN, Day 3, n= 16 | 0.312 ± 0.5567 |
| BUN, Day 7, n= 15 | -0.031 ± 0.5038 |
| BUN, Day 9, n= 15 | -0.028 ± 0.4521 |
Blood samples were collected at indicated time-points for analysis of clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Day -1 for Period 1.
| Millimoles per Liter | TAF/FTC |
|---|---|
| Glucose, Baseline | 5.111 ± 0.3747 |
| Glucose, Day 7 | 4.951 ± 0.2587 |
| Glucose, Day 14 | 4.791 ± 0.2662 |
| Cholesterol, Baseline | 4.253 ± 0.7938 |
| Cholesterol, Day 7 | 4.249 ± 0.8494 |
| Cholesterol, Day 14 | 3.864 ± 0.6087 |
| Anion gap, Baseline | 8.7 ± 1.08 |
| Anion gap, Day 7 | 10.6 ± 2.25 |
| Anion gap, Day 14 | 10.9 ± 1.45 |
| Calcium, Baseline | 2.359 ± 0.0697 |
| Calcium, Day 7 | 2.387 ± 0.0663 |
| Calcium, Day 14 | 2.387 ± 0.0637 |
| CO2, Baseline | 31.7 ± 1.49 |
| CO2, Day 7 | 30.1 ± 1.86 |
| CO2, Day 14 | 30.8 ± 1.38 |
| Chloride, Baseline | 103.3 ± 1.84 |
| Chloride, Day 7 | 102.2 ± 1.72 |
| Chloride, Day 14 | 101.3 ± 2.32 |
| Phosphate, Baseline | 1.078 ± 0.1301 |
| Phosphate, Day 7 | 1.094 ± 0.1202 |
| Phosphate, Day 14 | 1.103 ± 0.0807 |
| Potassium, Baseline | 4.25 ± 0.225 |
| Potassium, Day 7 | 4.28 ± 0.161 |
| Potassium, Day 14 | 4.22 ± 0.279 |
| Sodium, Baseline | 139.4 ± 1.45 |
| Sodium, Day 7 | 138.8 ± 1.77 |
| Sodium, Day 14 | 138.8 ± 1.69 |
| Triglycerides, Baseline | 1.076 ± 0.5825 |
| Triglycerides, Day 7 | 1.168 ± 0.3759 |
| Triglycerides, Day 14 | 1.033 ± 0.3034 |
| BUN, Baseline | 4.441 ± 1.2792 |
| BUN, Day 7 | 4.423 ± 0.9623 |
| BUN, Day 14 | 4.246 ± 0.7820 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of glucose, calcium, potassium, sodium, BUN, anion gap, CO2, chloride and phosphorus. Baseline was defined as Period 1 Day 14 for Period 2.
| Millimoles per Liter | TAF/FTC+GSK3640254 |
|---|---|
| Glucose, Baseline, n= 16 | 4.791 ± 0.2662 |
| Glucose, Day 3, n= 15 | 5.027 ± 0.2894 |
| Glucose, Day 7, n= 15 | 5.129 ± 0.3388 |
| Glucose, Day 9, n= 15 | 4.950 ± 0.3360 |
| Cholesterol, Baseline, n= 16 | 3.864 ± 0.6087 |
| Cholesterol, Day 3, n=15 | 3.875 ± 0.6509 |
| Cholesterol, Day 7, n= 15 | 3.894 ± 0.7575 |
| Cholesterol, Day 9, n= 16 | 3.822 ± 0.7838 |
| Anion gap, Baseline, n= 16 | 10.9 ± 1.45 |
| Anion gap, Day 3, n= 16 | 10.5 ± 1.37 |
| Anion gap, Day 7, n= 15 | 10.3 ± 1.28 |
| Anion gap, Day 9, n= 15 | 10.5 ± 0.74 |
| Calcium, Baseline, n= 16 | 2.387 ± 0.0637 |
| Calcium, Day 3, n= 16 | 2.399 ± 0.0682 |
| Calcium, Day 7, n= 15 | 2.424 ± 0.0693 |
| Calcium, Day 9, n= 15 | 2.421 ± 0.0670 |
| CO2, Baseline, n= 16 | 30.8 ± 1.38 |
| CO2, Day 3, n= 16 | 30.3 ± 1.96 |
| CO2, Day 7, n= 15 | 30.7 ± 1.91 |
| CO2, Day 9, n= 15 | 30.5 ± 1.30 |
| Chloride, Baseline, n= 16 | 101.3 ± 2.32 |
| Chloride, Day 3, n= 16 | 103.6 ± 1.50 |
| Chloride, Day 7, n= 15 | 101.9 ± 1.62 |
| Chloride, Day 9, n= 15 | 102.7 ± 1.50 |
| Phosphate, Baseline, n= 16 | 1.103 ± 0.0807 |
| Phosphate, Day 3, n= 16 | 1.165 ± 0.1007 |
| Phosphate, Day 7, n= 15 | 1.112 ± 0.1097 |
| Phosphate, Day 9, n= 15 | 1.117 ± 0.0952 |
| Potassium, Baseline, n= 16 | 4.22 ± 0.279 |
| Potassium, Day 3, n= 16 | 4.23 ± 0.241 |
| Potassium, Day 7, n= 15 | 4.21 ± 0.236 |
| Potassium, Day 9, n= 15 | 4.35 ± 0.226 |
| Sodium, Baseline, n= 16 | 138.8 ± 1.69 |
| Sodium, Day 3, n= 16 | 140.2 ± 1.56 |
| Sodium, Day 7, n= 15 | 138.8 ± 1.42 |
| Sodium, Day 9, n=15 | 139.3 ± 1.18 |
| Triglycerides, Baseline, n= 16 | 1.033 ± 0.3034 |
| Triglycerides, Day 3, n= 16 | 1.029 ± 0.3440 |
| Triglycerides, Day 7, n= 15 | 1.120 ± 0.4358 |
| Triglycerides, Day 9, n= 15 | 0.961 ± 0.4320 |
| BUN, Baseline, n= 16 | 4.246 ± 0.7820 |
| BUN, Day 3, n= 16 | 4.558 ± 0.8267 |
| BUN, Day 7, n= 15 | 4.260 ± 0.8705 |
| BUN Day 9, n= 15 | 4.263 ± 0.6977 |
Blood samples were collected at indicated time-points for analysis of clinical chemistry parameter like alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| International units per Liter | TAF/FTC |
|---|---|
| Alkaline phosphatase, Day 7 | -2.6 ± 5.10 |
| Alkaline phosphatase, Day 14 | 2.4 ± 6.91 |
| AST, Day 7 | -6.2 ± 4.59 |
| AST, Day 14 | -6.9 ± 4.95 |
| ALT, Day 7 | -2.1 ± 7.26 |
| ALT, Day 14 | -6.2 ± 6.98 |
| GGT Day 7 | 0.2 ± 2.32 |
| GGT Day 14 | -1.7 ± 3.63 |
| LDH, Day 7 | -14.6 ± 13.07 |
| LDH, Day 14 | -12.0 ± 16.25 |
| CK, Day 7 | -103.0 ± 127.10 |
| CK, Day 14 | -99.2 ± 135.80 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| International units per Liter | TAF/FTC+GSK3640254 |
|---|---|
| Alkaline phosphatase, Day 3, n= 16 | 3.7 ± 3.48 |
| Alkaline phosphatase, Day 7, n= 15 | 2.6 ± 3.64 |
| Alkaline phosphatase, Day 9, n= 15 | -1.0 ± 3.98 |
| AST, Day 3, n= 16 | -1.4 ± 1.31 |
| AST, Day 7, n= 15 | -0.5 ± 2.45 |
| AST, Day 9, n= 15 | -0.1 ± 2.13 |
| ALT, Day 3, n= 16 | -2.0 ± 1.63 |
| ALT, Day 7, n= 15 | -1.9 ± 2.76 |
| ALT, Day 9, n= 15 | -0.7 ± 4.56 |
| GGT, Day 3, n= 16 | -0.9 ± 1.18 |
| GGT, Day 7, n= 15 | -1.4 ± 1.50 |
| GGT, Day 9, n= 15 | -1.9 ± 2.55 |
| LDH, Day 3, n= 16 | -7.0 ± 11.98 |
| LDH, Day 7, n= 15 | -8.2 ± 12.73 |
| LDH, Day 9, n= 15 | -7.0 ± 11.98 |
| CK, Day 3, n= 16 | 3.4 ± 29.12 |
| CK, Day 7, n= 15 | 11.3 ± 33.83 |
| CK, Day 9, n= 15 | -2.3 ± 22.65 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Day -1 for Period 1.
| International units per Liter | TAF/FTC |
|---|---|
| Alkaline phosphatase, Baseline | 60.9 ± 9.33 |
| Alkaline phosphatase, Day 7 | 58.3 ± 8.36 |
| Alkaline phosphatase, Day 14 | 63.4 ± 8.82 |
| AST, Baseline | 24.6 ± 6.16 |
| AST, Day 7 | 18.4 ± 4.79 |
| AST, Day 14 | 17.6 ± 3.46 |
| ALT, Baseline | 26.6 ± 10.44 |
| ALT, Day 7 | 24.4 ± 13.28 |
| ALT, Day 14 | 20.4 ± 8.59 |
| GGT Baseline | 1.76 ± 1.016 |
| GGT Day 7 | 1.91 ± 0.752 |
| GGT Day 14 | 2.40 ± 1.035 |
| LDH, Baseline | 138.0 ± 19.77 |
| LDH, Day 7 | 123.4 ± 19.67 |
| LDH, Day 9 | 126.0 ± 19.50 |
| CK, Baseline | 219.6 ± 150.90 |
| CK, Day 7 | 116.6 ± 49.16 |
| CK, Day 14 | 120.4 ± 62.41 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of alkaline phosphatase, ALT, AST, LDH, GGT and CK. Baseline was defined as Period 1 Day 14 for Period 2.
| International units per Liter | TAF/FTC+GSK3640254 |
|---|---|
| Alkaline phosphatase, Baseline Day 3, n= 16 | 63.4 ± 8.82 |
| Alkaline phosphatase, Day 3, n= 16 | 67.1 ± 10.45 |
| Alkaline phosphatase, Day 7, n= 15 | 65.4 ± 9.81 |
| Alkaline phosphatase, Day 9, n= 15 | 61.8 ± 9.65 |
| AST, Baseline, n= 16 | 17.6 ± 3.46 |
| AST, Day 3, n= 16 | 16.2 ± 3.04 |
| AST, Day 7, n= 15 | 17.2 ± 3.38 |
| AST, Day 9, n= 15 | 17.6 ± 3.83 |
| ALT, Baseline, n= 16 | 20.4 ± 8.59 |
| ALT, Day 3, n= 16 | 18.4 ± 7.87 |
| ALT, Day 7, n= 15 | 18.5 ± 8.31 |
| ALT, Day 9, n= 15 | 19.7 ± 9.43 |
| GGT, Baseline, n= 16 | 2.40 ± 1.035 |
| GGT, Day 3, n= 16 | 2.14 ± 1.065 |
| GGT, Day 7, n= 15 | 2.41 ± 0.828 |
| GGT, Day 9, n= 15 | 1.95 ± 0.673 |
| LDH, Baseline, n= 16 | 126.0 ± 19.50 |
| LDH, Day 3, n= 16 | 119.0 ± 19.37 |
| LDH, Day 7, n= 15 | 118.0 ± 13.93 |
| LDH, Day 9, n= 15 | 119.2 ± 17.70 |
| CK, Baseline, n= 16 | 120.4 ± 62.41 |
| CK, Day 3, n= 16 | 123.8 ± 51.53 |
| CK, Day 7, n= 15 | 135.8 ± 66.33 |
| CK, Day 9, n= 15 | 122.2 ± 54.94 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Units per Liter | TAF/FTC |
|---|---|
| Amylase, Day 7 | -2.3 ± 9.68 |
| Amylase, Day 14 | -2.8 ± 10.48 |
| Lipase, Day 7 | -4.0 ± 8.93 |
| Lipase, Day 14 | -5.3 ± 12.69 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Units per Liter | TAF/FTC+GSK3640254 |
|---|---|
| Amylase, Day 3, n= 16 | 3.3 ± 8.93 |
| Amylase, Day 7, n= 15 | -1.9 ± 6.77 |
| Amylase, Day 9, n= 15 | 1.1 ± 6.32 |
| Lipase, Day 3, n= 16 | 7.7 ± 21.62 |
| Lipase, Day 7, n= 15 | 0.0 ± 8.20 |
| Lipase, Day 9, n= 15 | 3.5 ± 3.89 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Day -1 for Period 1.
| Units per Liter | TAF/FTC |
|---|---|
| Amylase, Baseline | 56.4 ± 14.66 |
| Amylase, Day 7 | 54.1 ± 13.15 |
| Amylase, Day 14 | 53.6 ± 14.48 |
| Lipase, Baseline | 22.2 ± 14.00 |
| Lipase, Day 7 | 18.2 ± 9.72 |
| Lipase, Day 14 | 16.9 ± 14.65 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of lipase and amylase. Baseline was defined as Period 1 Day 14 for Period 2.
| Units per Liter | TAF/FTC+GSK3640254 |
|---|---|
| Amylase, Baseline, n= 16 | 53.6 ± 14.48 |
| Amylase, Day 3, n= 16 | 56.8 ± 19.32 |
| Amylase, Day 7, n= 15 | 52.7 ± 12.97 |
| Amylase, Day 9, n= 15 | 55.7 ± 13.39 |
| Lipase, Baseline, n= 16 | 16.9 ± 14.65 |
| Lipase, Day 3, n= 16 | 24.6 ± 34.82 |
| Lipase, Day 7, n= 15 | 17.5 ± 10.69 |
| Lipase, Day 9, n= 15 | 21.0 ± 14.16 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Micromoles per liter | TAF/FTC |
|---|---|
| Creatinine, Day 7 | 5.69 ± 3.508 |
| Creatinine, Day 14 | 7.36 ± 4.833 |
| Total bilirubin, Day 7 | 2.25 ± 4.756 |
| Total bilirubin, Day 14 | 2.10 ± 5.109 |
| Direct bilirubin, Day 7 | 0.15 ± 0.634 |
| Direct bilirubin, Day 14 | 0.64 ± 0.699 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Micromoles per liter | TAF/FTC+GSK3640254 |
|---|---|
| Creatinine, Day 3, n= 16 | -2.34 ± 3.755 |
| Creatinine, Day 7, n= 15 | 3.53 ± 3.802 |
| Creatinine, Day 9, n= 15 | 0.28 ± 3.569 |
| Total bilirubin, Day 3, n= 16 | -0.82 ± 3.475 |
| Total bilirubin, Day 7, n= 15 | -0.26 ± 2.466 |
| Total bilirubin, Day 9, n= 15 | -1.91 ± 2.252 |
| Direct bilirubin, Day 3, n= 16 | -0.26 ± 0.534 |
| Direct bilirubin, Day 7, n= 15 | -0.03 ± 0.547 |
| Direct bilirubin, Day 9, n= 15 | -0.49 ± 0.501 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, and creatinine. Baseline was defined as Day -1 for Period 1.
| Micromoles per liter | TAF/FTC |
|---|---|
| Creatinine, Baseline | 80.16 ± 10.103 |
| Creatinine, Day 7 | 85.85 ± 9.586 |
| Creatinine, Day 14 | 87.52 ± 10.058 |
| Total bilirubin, Baseline | 9.64 ± 6.143 |
| Total bilirubin, Day 7 | 11.89 ± 6.781 |
| Total bilirubin, Day 14 | 11.74 ± 7.046 |
| Direct bilirubin, Baseline | 1.76 ± 1.016 |
| Direct bilirubin, Day 7 | 1.91 ± 0.752 |
| Direct bilirubin, Day 14 | 2.40 ± 1.035 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, creatinine and uric acid. Baseline was defined as Period 1 Day 14 for Period 2.
| Micromoles per liter | TAF/FTC+GSK3640254 |
|---|---|
| Creatinine, Baseline, n= 16 | 87.52 ± 10.058 |
| Creatinine, Day 3, n= 16 | 85.18 ± 10.314 |
| Creatinine, Day 7, n= 15 | 91.53 ± 9.504 |
| Creatinine, Day 9, n= 15 | 88.27 ± 9.916 |
| Total bilirubin, Baseline, n= 16 | 11.44 ± 6.022 |
| Total bilirubin, Day 3, n= 16 | 10.62 ± 7.886 |
| Total bilirubin, Day 7, n= 15 | 11.33 ± 5.487 |
| Total bilirubin, Day 9, n= 15 | 9.68 ± 4.603 |
| Direct bilirubin, Baseline, n= 16 | 2.40 ± 1.035 |
| Direct bilirubin, Day 3, n= 16 | 2.14 ± 1.065 |
| Direct bilirubin, Day 7, n= 15 | 2.41 ± 0.828 |
| Direct bilirubin, Day 9, n= 15 | 1.95 ± 0.673 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of of total protein, albumin and globulin. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Grams per Liter | TAF/FTC |
|---|---|
| Total Protein, Day 7 | 2.6 ± 3.20 |
| Total Protein, Day 14 | 2.9 ± 2.66 |
| Globulin, Day 7 | 2.5 ± 1.37 |
| Globulin, Day 14 | 2.8 ± 1.91 |
| Albumin, Day 7 | 0.1 ± 2.22 |
| Albumin, Day 14 | 0.1 ± 2.05 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total protein, albumin and globulin. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Grams per Liter | TAF/FTC+GSK3640254 |
|---|---|
| Total Protein, Day 3, n= 16 | 0.1 ± 2.68 |
| Total Protein, Day 7, n= 15 | 3.1 ± 2.85 |
| Total Protein, Day 9, n= 15 | 0.8 ± 3.28 |
| Globulin, Day 3, n= 16 | 0.2 ± 1.17 |
| Globulin, Day 7, n= 15 | 2.3 ± 0.96 |
| Globulin, Day 9, n= 15 | 0.2 ± 1.08 |
| Albumin, Day 3, n= 16 | -0.1 ± 1.95 |
| Albumin, Day 7, n= 15 | 0.9 ± 2.20 |
| Albumin, Day 9, n= 15 | 0.6 ± 2.50 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total protein, albumin and globulin. Baseline was defined as Day -1 for Period 1.
| Grams per Liter | TAF/FTC |
|---|---|
| Total Protein, Baseline | 69.8 ± 3.64 |
| Total Protein, Day 7 | 72.4 ± 3.70 |
| Total Protein, Day 14 | 72.6 ± 3.10 |
| Globulin, Baseline | 25.9 ± 2.50 |
| Globulin, Day 7 | 28.4 ± 2.60 |
| Globulin, Day 14 | 28.7 ± 1.99 |
| Albumin, Baseline | 43.9 ± 2.36 |
| Albumin, Day 7 | 44.0 ± 1.90 |
| Albumin, Day 14 | 43.9 ± 2.41 |
Blood samples were collected at indicated time-points for analysis for clinical chemistry parameter of total bilirubin, direct bilirubin, creatinine and uric acid. Baseline was defined as Period 1 Day 14 for Period 2.
| Grams per Liter | TAF/FTC+GSK3640254 |
|---|---|
| Total Protein, Baseline, n= 16 | 72.6 ± 3.10 |
| Total Protein, Day 3, n= 16 | 72.8 ± 2.96 |
| Total Protein, Day 7, n= 15 | 75.7 ± 2.89 |
| Total Protein, Day 9, n= 15 | 73.3 ± 2.61 |
| Globulin, Baseline, n= 16 | 28.7 ± 1.99 |
| Globulin, Day 3, n= 16 | 28.9 ± 2.31 |
| Globulin, Day 7, n= 15 | 30.9 ± 1.96 |
| Globulin, Day 9, n= 15 | 28.8 ± 1.90 |
| Albumin, Baseline, n= 16 | 43.9 ± 2.41 |
| Albumin, Day 3, n= 16 | 43.9 ± 1.89 |
| Albumin, Day 7, n= 15 | 44.8 ± 2.08 |
| Albumin, Day 9, n= 15 | 44.5 ± 1.73 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Ratio | TAF/FTC |
|---|---|
| Day 7 | 0.0007 ± 0.01085 |
| Day 14 | 0.0011 ± 0.00941 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Ratio | TAF/FTC+GSK3640254 |
|---|---|
| Day 3, n= 16 | 0.0031 ± 0.00666 |
| Day 7, n= 15 | 0.0024 ± 0.00608 |
| Day 9, n= 15 | 0.0005 ± 0.00872 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Day -1 for Period 1.
| Ratio | TAF/FTC |
|---|---|
| Baseline | 1.0136 ± 0.01095 |
| Day 7 | 1.0143 ± 0.00556 |
| Day 14 | 1.0147 ± 0.00789 |
Urine samples were collected at indicated time points for the assessment of specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. Baseline was defined as Period 1 Day 14 for Period 2.
| Ratio | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 1.0147 ± 0.00789 |
| Day 3, n= 16 | 1.0178 ± 0.00584 |
| Day 7, n= 15 | 1.0170 ± 0.00655 |
| Day 9, n= 15 | 1.0151 ± 0.00788 |
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| pH | TAF/FTC |
|---|---|
| Day 7 | -0.34 ± 0.397 |
| Day 14 | -0.19 ± 0.544 |
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| pH | TAF/FTC+GSK3640254 |
|---|---|
| Day 3, n= 16 | 0.19 ± 0.479 |
| Day 7, n= 15 | 0.10 ± 0.471 |
| Day 9, n= 15 | 0.10 ± 0.507 |
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Day -1 for Period 1.
| pH | TAF/FTC |
|---|---|
| Baseline | 6.22 ± 0.446 |
| Day 7 | 5.88 ± 0.289 |
| Day 14 | 6.03 ± 0.531 |
Urine samples were collected at indicated time points for the assessment of Urinary pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Baseline was defined as Period 1 Day 14 for Period 2.
| pH | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 6.03 ± 0.531 |
| Day 3, n= 16 | 6.22 ± 0.482 |
| Day 7, n= 15 | 6.07 ± 0.320 |
| Day 9, n= 15 | 6.07 ± 0.320 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Micromoles per liter | TAF/FTC |
|---|---|
| Day 7 | -2.5395 ± 5.45976 |
| Day 14 | -2.5395 ± 5.45976 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Period 1 Day 14 for Period 2. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Micromoles per liter | TAF/FTC+GSK3640254 |
|---|---|
| Day 3, n= 16 | 0.0000 ± 0.00000 |
| Day 7, n= 15 | 0.0000 ± 0.00000 |
| Day 9, n= 15 | 0.0000 ± 0.00000 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1.
| Micromoles per liter | TAF/FTC |
|---|---|
| Baseline | 5.9255 ± 5.45976 |
| Day 7 | 3.3860 ± 0.0000 |
| Day 14 | 3.3860 ± 0.0000 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Period 1 Day 14 for Period 2.
| Micromoles per liter | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 3.3860 ± 0.0000 |
| Day 3, n= 16 | 3.3860 ± 0.0000 |
| Day 7, n= 15 | 3.3860 ± 0.0000 |
| Day 9, n= 15 | 3.3860 ± 0.0000 |
Urine samples were collected at indicated time points for the assessment of urine urobilinogen. Baseline was defined as Day -1 for Period 1. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Beats per minute | TAF/FTC |
|---|---|
| Day 1, 2 hours post-dose | 1.5 ± 6.87 |
| Day 1, 4 hours post-dose | -3.3 ± 10.37 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Beats per minute | TAF/FTC+GSK3640254 |
|---|---|
| Day 1, 2 hours post-dose, n= 16 | 5.0 ± 4.37 |
| Day 1, 4 hours post-dose, n= 16 | 2.8 ± 6.62 |
| Day 4, Pre-dose, n= 15 | -0.5 ± 11.10 |
| Day 4, 2 hours post-dose, n= 15 | 3.3 ± 5.86 |
| Day 4, 4 hours post-dose, n= 15 | -0.3 ± 5.13 |
| Day 7, Pre-dose, n= 15 | 0.3 ± 11.18 |
| Day 7, 2 hours post-dose, n= 15 | 1.8 ± 6.72 |
| Day 7, 4 hours post-dose, n= 15 | -2.3 ± 7.08 |
| Day 9 post-dose, n= 15 | 2.1 ± 7.84 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Beats per minute | TAF/FTC |
|---|---|
| Baseline | 67.6 ± 8.72 |
| Day 1, 2 hours post-dose | 69.1 ± 11.04 |
| Day 1, 4 hours post-dose | 64.4 ± 11.87 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure heart rate. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Beats per minute | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 66.5 ± 8.06 |
| Day 1, 2 hours post-dose, n= 16 | 71.5 ± 9.95 |
| Day 1, 4 hours post-dose, n= 16 | 69.3 ± 11.38 |
| Day 4, Pre-dose, n= 15 | 65.1 ± 10.48 |
| Day 4, 2 hours post-dose, n= 15 | 68.9 ± 8.00 |
| Day 4, 4 hours post-dose, n= 15 | 65.3 ± 8.97 |
| Day 7, Pre-dose, n= 15 | 65.9 ± 10.25 |
| Day 7, 2 hours post-dose, n= 15 | 67.4 ± 6.39 |
| Day 7, 4 hours post-dose, n= 15 | 63.3 ± 8.31 |
| Day 9 post-dose, n= 15 | 67.7 ± 9.23 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interal, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Milliseconds | TAF/FTC |
|---|---|
| PR Interval, Day 1, 2 hours post-dose | 1.5 ± 9.67 |
| PR Interval, Day 1, 4 hours post-dose | -1.9 ± 8.64 |
| QRS Duration, Day 1, 2 hours post-dose | -1.1 ± 3.68 |
| QRS Duration, Day 1, 4 hours post-dose | 0.3 ± 4.96 |
| QT Interval, Day 1, 2 hours post-dose | -7.5 ± 14.12 |
| QT Interval, Day 1, 4 hours post-dose | 5.8 ± 23.18 |
| QTcF Interval, Day 1, 2 hours post-dose | -4.9 ± 10.63 |
| QTcF Interval, Day 1, 4 hours post-dose | -1.3 ± 10.56 |
| QTcB Interval, Day 1, 2 hours post-dose | -4.1 ± 12.70 |
| QTcB Interval, Day 1, 4 hours post-dose | -5.4 ± 12.39 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interal, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Milliseconds | TAF/FTC+GSK3640254 |
|---|---|
| PR Interval, Day 1, 2 hours post-dose, n= 16 | -6.8 ± 6.77 |
| PR Interval, Day 1, 4 hours post-dose, n= 16 | -3.7 ± 5.99 |
| PR Interval, Day 4, Pre-dose, n= 15 | -0.5 ± 4.56 |
| PR Interval, Day 4, 2 hours post-dose, n= 15 | -6.9 ± 6.67 |
| PR Interval, Day 4, 4 hours post-dose, n= 15 | -3.9 ± 7.83 |
| PR Interval, Day 7, Pre-dose, n= 15 | -2.7 ± 8.57 |
| PR Interval, Day 7, 2 hours post-dose, n= 15 | -3.3 ± 7.06 |
| PR Interval, Day 7, 4 hours post-dose, n= 15 | -3.7 ± 8.53 |
| PR Interval, Day 9 post-dose, n= 15 | 1.2 ± 6.42 |
| QRS Duration, Day 1, 2 hours post-dose, n= 16 | -2.5 ± 4.40 |
| QRS Duration, Day 1, 4 hours post-dose, n= 16 | -1.4 ± 4.69 |
| QRS Duration, Day 4, Pre-dose, n= 15 | 0.5 ± 3.44 |
| QRS Duration, Day 4, 2 hours post-dose, n= 15 | 0.5 ± 5.72 |
| QRS Duration, Day 4, 4 hours post-dose, n= 15 | -0.2 ± 2.70 |
| QRS Duration, Day 7, Pre-dose, n= 15 | 3.3 ± 4.53 |
| QRS Duration, Day 7, 2 hours post-dose, n= 15 | 1.5 ± 5.15 |
| QRS Duration, Day 7, 4 hours post-dose, n= 15 | 0.3 ± 3.72 |
| QRS Duration, Day 9 post-dose, n= 15 | 3.0 ± 5.36 |
| QT Interval, Day 1, 2 hours post-dose, n= 16 | -12.6 ± 9.11 |
| QT Interval, Day 1, 4 hours post-dose, n= 16 | -1.8 ± 14.72 |
| QT Interval, Day 4, Pre-dose, n= 15 | 7.3 ± 18.27 |
| QT Interval, Day 4, 2 hours post-dose, n= 15 | -6.8 ± 15.72 |
| QT Interval, Day 4, 4 hours post-dose, n= 15 | 5.6 ± 14.64 |
| QT Interval, Day 7, Pre-dose, n= 15 | 3.5 ± 18.31 |
| QT Interval, Day 7, 2 hours post-dose, n= 15 | -8.4 ± 16.15 |
| QT Interval, Day 7, 4 hours post-dose, n= 15 | 5.8 ± 17.37 |
| QT Interval, Day 9 post-dose, n= 15 | 4.1 ± 16.46 |
| QTcF Interval, Day 1, 2 hours post-dose, n= 16 | -4.4 ± 7.29 |
| QTcF Interval, Day 1, 4 hours post-dose, n= 16 | 2.4 ± 7.77 |
| QTcF Interval, Day 4, Pre-dose, n= 15 | 6.1 ± 11.17 |
| QTcF Interval, Day 4, 2 hours post-dose, n= 15 | -0.6 ± 10.91 |
| QTcF Interval, Day 4, 4 hours post-dose, n= 15 | 4.5 ± 8.22 |
| QTcF Interval, Day 7, Pre-dose, n= 15 | 4.1 ± 8.71 |
| QTcF Interval, Day 7, 2 hours post-dose, n= 15 | -5.1 ± 9.34 |
| QTcF Interval, Day 7, 4 hours post-dose, n= 15 | 0.6 ± 9.03 |
| QTcF Interval, Day 9 post-dose, n= 15 | 7.9 ± 8.53 |
| QTcB Interval, Day 1, 2 hours post-dose, n= 16 | 0.7 ± 8.83 |
| QTcB Interval, Day 1, 4 hours post-dose, n= 16 | 4.7 ± 8.49 |
| QTcB Interval, Day 4, Pre-dose, n= 15 | 5.5 ± 18.50 |
| QTcB Interval, Day 4, 2 hours post-dose, n= 15 | 2.5 ± 12.37 |
| QTcB Interval, Day 4, 4 hours post-dose, n= 15 | 4.3 ± 8.52 |
| QTcB Interval, Day 7, Pre-dose, n= 15 | 4.6 ± 16.31 |
| QTcB Interval, Day 7, 2 hours post-dose, n= 15 | -3.2 ± 11.64 |
| QTcB Interval, Day 7, 4 hours post-dose, n= 15 | -1.7 ± 12.06 |
| QTcB Interval, Day 9 post-dose, n= 15 | 10.3 ± 12.19 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Milliseconds | TAF/FTC |
|---|---|
| PR Interval, Baseline | 161.3 ± 16.53 |
| PR Interval, Day 1, 2 hours post-dose | 162.8 ± 19.01 |
| PR Interval, Day 1, 4 hours post-dose | 159.4 ± 19.47 |
| QRS Duration, Baseline | 91.0 ± 8.22 |
| QRS Duration, Day 1, 2 hours post-dose | 89.9 ± 7.54 |
| QRS Duration, Day 1, 4 hours post-dose | 91.3 ± 8.14 |
| QT Interval, Baseline | 377.8 ± 24.84 |
| QT Interval, Day 1, 2 hours post-dose | 370.3 ± 24.74 |
| QT Interval, Day 1, 4 hours post-dose | 383.6 ± 32.12 |
| QTcF Interval, Baseline | 391.6 ± 12.92 |
| QTcF Interval, Day 1, 2 hours post-dose | 386.7 ± 14.33 |
| QTcF Interval, Day 1, 4 hours post-dose | 390.3 ± 18.27 |
| QTcB Interval, Baseline | 398.8 ± 11.28 |
| QTcB Interval, Day 1, 2 hours post-dose | 394.6 ± 15.14 |
| QTcB Interval, Day 1, 4 hours post-dose | 393.3 ± 18.26 |
Twelve-lead ECGs was performed with the participant in a supine or semi-supine position after a rest of at least 10 minutes using an automated ECG machine to measure PR interval, QRS duration, QT Interval, QTcF Interval and QTcB interval. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Milliseconds | TAF/FTC+GSK3640254 |
|---|---|
| PR Interval, Baseline, n= 16 | 167.3 ± 19.46 |
| PR Interval, Day 1, 2 hours post-dose, n= 16 | 160.4 ± 19.73 |
| PR Interval, Day 1, 4 hours post-dose, n= 16 | 163.6 ± 19.04 |
| PR Interval, Day 4, Pre-dose, n= 15 | 167.1 ± 22.20 |
| PR Interval, Day 4, 2 hours post-dose, n= 15 | 160.7 ± 19.59 |
| PR Interval, Day 4, 4 hours post-dose, n= 15 | 163.7 ± 19.29 |
| PR Interval, Day 7, Pre-dose, n= 15 | 164.9 ± 21.11 |
| PR Interval, Day 7, 2 hours post-dose, n= 15 | 164.3 ± 20.95 |
| PR Interval, Day 7, 4 hours post-dose, n= 15 | 163.9 ± 22.05 |
| PR Interval, Day 9 post-dose, n= 15 | 168.8 ± 23.70 |
| QRS Duration, Baseline, n= 16 | 91.4 ± 7.87 |
| QRS Duration, Day 1, 2 hours post-dose, n= 16 | 88.9 ± 8.20 |
| QRS Duration, Day 1, 4 hours post-dose, n= 16 | 90.1 ± 7.66 |
| QRS Duration, Day 4, Pre-dose, n= 15 | 91.8 ± 8.37 |
| QRS Duration, Day 4, 2 hours post-dose, n= 15 | 91.8 ± 9.12 |
| QRS Duration, Day 4, 4 hours post-dose, n= 15 | 91.1 ± 8.51 |
| QRS Duration, Day 7, Pre-dose, n= 15 | 94.5 ± 8.25 |
| QRS Duration, Day 7, 2 hours post-dose, n= 15 | 92.7 ± 7.49 |
| QRS Duration, Day 7, 4 hours post-dose, n= 15 | 91.6 ± 7.23 |
| QRS Duration, Day 9 post-dose, n= 15 | 94.3 ± 8.17 |
| QT Interval, Baseline, n= 16 | 377.7 ± 22.66 |
| QT Interval, Day 1, 2 hours post-dose, n= 16 | 365.1 ± 23.71 |
| QT Interval, Day 1, 4 hours post-dose, n= 16 | 375.9 ± 30.14 |
| QT Interval, Day 4, Pre-dose, n= 15 | 385.6 ± 26.65 |
| QT Interval, Day 4, 2 hours post-dose, n= 15 | 371.5 ± 27.31 |
| QT Interval, Day 4, 4 hours post-dose, n= 15 | 383.9 ± 31.05 |
| QT Interval, Day 7, Pre-dose, n= 15 | 381.7 ± 22.25 |
| QT Interval, Day 7, 2 hours post-dose, n= 15 | 369.9 ± 25.66 |
| QT Interval, Day 7, 4 hours post-dose, n= 15 | 384.1 ± 30.53 |
| QT Interval, Day 9 post-dose, n= 15 | 382.4 ± 26.55 |
| QTcF Interval, Baseline, n= 16 | 390.0 ± 13.48 |
| QTcF Interval, Day 1, 2 hours, n= 16 | 385.6 ± 15.44 |
| QTcF Interval, Day 1, 4 hours post-dose, n= 16 | 392.4 ± 15.95 |
| QTcF Interval, Day 4, Pre-dose, n= 15 | 395.0 ± 21.88 |
| QTcF Interval, Day 4, 2 hours post-dose, n= 15 | 388.3 ± 17.56 |
| QTcF Interval, Day 4, 4 hours post-dose, n= 15 | 393.4 ± 18.97 |
| QTcF Interval, Day 7, Pre-dose, n= 15 | 393.0 ± 18.42 |
| QTcF Interval, Day 7, 2 hours post-dose, n= 15 | 383.8 ± 16.19 |
| QTcF Interval, Day 7, 4 hours post-dose, n= 15 | 389.5 ± 18.06 |
| QTcF Interval, Day 9 post-dose, n= 15 | 396.8 ± 18.51 |
| QTcB Interval, Baseline, n= 16 | 395.7 ± 14.19 |
| QTcB Interval, Day 1, 2 hours post-dose, n= 16 | 396.4 ± 17.29 |
| QTcB Interval, Day 1, 4 hours post-dose, n= 16 | 400.4 ± 16.20 |
| QTcB Interval, Day 4, Pre-dose, n= 15 | 399.2 ± 25.96 |
| QTcB Interval, Day 4, 2 hours post-dose, n= 15 | 396.2 ± 16.01 |
| QTcB Interval, Day 4, 4 hours post-dose, n= 15 | 398.0 ± 17.53 |
| QTcB Interval, Day 7, Pre-dose, n= 15 | 398.3 ± 23.83 |
| QTcB Interval, Day 7, 2 hours post-dose, n= 15 | 390.5 ± 13.31 |
| QTcB Interval, Day 7, 4 hours post-dose, n= 15 | 391.9 ± 16.35 |
| QTcB Interval, Day 9 post-dose, n= 15 | 404.0 ± 20.62 |
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Degree Celsius | TAF/FTC |
|---|---|
| Day 2 | -0.16 ± 0.400 |
| Day 3 | -0.15 ± 0.576 |
| Day 4 | -0.09 ± 0.406 |
| Day 5 | -0.15 ± 0.371 |
| Day 7 | -0.24 ± 0.491 |
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Degree Celsius | TAF/FTC+GSK3640254 |
|---|---|
| Day 4 | -0.10 ± 0.344 |
| Day 7 | -0.07 ± 0.337 |
| Day 9 | -0.01 ± 0.386 |
| Day 10 | 0.07 ± 0.320 |
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Degree Celsius | TAF/FTC |
|---|---|
| Baseline | 36.49 ± 0.298 |
| Day 2 | 36.33 ± 0.342 |
| Day 3 | 36.34 ± 0.456 |
| Day 4 | 36.41 ± 0.431 |
| Day 5 | 36.34 ± 0.360 |
| Day 7 | 36.25 ± 0.407 |
Temperature was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Degree Celsius | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 36.49 ± 0.257 |
| Day 4, n=15 | 36.37 ± 0.348 |
| Day 7, n=15 | 36.40 ± 0.421 |
| Day 9, n=15 | 36.46 ± 0.378 |
| Day 10, n=15 | 36.53 ± 0.282 |
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Beats per minute | TAF/FTC |
|---|---|
| Day 2 | -1.2 ± 9.77 |
| Day 3 | -3.8 ± 9.94 |
| Day 4 | -4.0 ± 9.67 |
| Day 5 | -1.6 ± 10.47 |
| Day 7 | -7.6 ± 7.83 |
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Beats per minute | TAF/FTC+GSK3640254 |
|---|---|
| Day 4 | 2.4 ± 18.62 |
| Day 7 | 1.9 ± 15.62 |
| Day 9 | -0.3 ± 10.20 |
| Day 10 | 9.5 ± 11.12 |
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Beats per minute | TAF/FTC |
|---|---|
| Baseline | 73.9 ± 9.24 |
| Day 2 | 72.8 ± 10.14 |
| Day 3 | 70.1 ± 11.18 |
| Day 4 | 69.9 ± 10.81 |
| Day 5 | 72.3 ± 12.38 |
| Day 7 | 66.3 ± 10.20 |
Pulse rate was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Beats per minute | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 70.5 ± 11.33 |
| Day 4, n=15 | 71.9 ± 18.39 |
| Day 7, n=15 | 71.4 ± 14.73 |
| Day 9, n=15 | 69.2 ± 10.73 |
| Day 10, n=15 | 79.0 ± 12.45 |
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Breaths per minute | TAF/FTC |
|---|---|
| Day 2 | -1.5 ± 2.00 |
| Day 3 | -0.5 ± 3.14 |
| Day 4 | -0.5 ± 2.37 |
| Day 5 | 1.3 ± 2.52 |
| Day 7 | 0.6 ± 3.24 |
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Breaths per minute | TAF/FTC+GSK3640254 |
|---|---|
| Day 4 | -3.2 ± 3.61 |
| Day 7 | -2.4 ± 2.85 |
| Day 9 | -0.8 ± 2.11 |
| Day 10 | -1.5 ± 2.33 |
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Breaths per minute | TAF/FTC |
|---|---|
| Baseline | 14.0 ± 1.63 |
| Day 2 | 12.5 ± 1.37 |
| Day 3 | 13.5 ± 2.48 |
| Day 4 | 13.5 ± 2.00 |
| Day 5 | 15.3 ± 2.05 |
| Day 7 | 14.6 ± 2.70 |
Respiratory rate was assessed at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Breaths per minute | TAF/FTC+GSK3640254 |
|---|---|
| Baseline, n= 16 | 15.6 ± 2.22 |
| Day 4, n=15 | 12.5 ± 2.67 |
| Day 7, n=15 | 13.3 ± 2.35 |
| Day 9, n=15 | 14.9 ± 1.49 |
| Day 10, n=15 | 14.3 ± 1.49 |
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Millimeters of mercury | TAF/FTC |
|---|---|
| SBP, Day 2 | 1.4 ± 8.96 |
| SBP, Day 3 | -1.8 ± 8.54 |
| SBP, Day 4 | -2.7 ± 6.16 |
| SBP, Day 5 | -2.3 ± 8.81 |
| SBP, Day 7 | 0.8 ± 9.47 |
| DBP, Day 2 | 0.1 ± 8.33 |
| DBP, Day 3 | -1.6 ± 7.20 |
| DBP, Day 4 | 0.1 ± 7.89 |
| DBP, Day 5 | -1.4 ± 6.20 |
| DBP, Day 7 | 2.9 ± 7.58 |
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Millimeters of mercury | TAF/FTC+GSK3640254 |
|---|---|
| SBP, Day 4 | -0.3 ± 5.07 |
| SBP, Day 7 | 1.1 ± 8.95 |
| SBP, Day 9 | -1.7 ± 6.91 |
| SBP, Day 10 | 4.1 ± 7.79 |
| DBP, Day 4 | 0.1 ± 4.96 |
| DBP, Day 7 | 3.7 ± 5.70 |
| DBP, Day 9 | -4.0 ± 5.26 |
| DBP, Day 10 | -2.1 ± 8.18 |
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Millimeters of mercury | TAF/FTC |
|---|---|
| SBP, Baseline | 123.3 ± 8.27 |
| SBP, Day 2 | 124.7 ± 9.60 |
| SBP, Day 3 | 121.5 ± 7.70 |
| SBP, Day 4 | 120.6 ± 8.47 |
| SBP, Day 5 | 121.0 ± 6.95 |
| SBP, Day 7 | 124.1 ± 10.56 |
| DBP, Baseline | 75.3 ± 5.22 |
| DBP, Day 2 | 75.4 ± 9.08 |
| DBP, Day 3 | 73.8 ± 5.69 |
| DBP, Day 4 | 75.4 ± 10.42 |
| DBP, Day 5 | 73.9 ± 5.46 |
| DBP, Day 7 | 78.2 ± 7.57 |
SBP and DBP was assessed in the semi-recumbent position with a completely automated device at indicated time-points. Baseline was defined as Day 1 (Pre-dose) for each Period.
| Millimeters of mercury | TAF/FTC+GSK3640254 |
|---|---|
| SBP, Baseline, n= 16 | 120.4 ± 7.27 |
| SBP, Day 4, n=15 | 119.3 ± 7.03 |
| SBP, Day 7, n=15 | 120.8 ± 10.58 |
| SBP, Day 9, n=15 | 117.9 ± 7.42 |
| SBP, Day 10, n=15 | 123.7 ± 8.52 |
| DBP, Baseline, n= 16 | 74.4 ± 6.14 |
| DBP, Day 4, n= 15 | 74.3 ± 5.16 |
| DBP, Day 7, n= 15 | 77.9 ± 8.98 |
| DBP, Day 9, n= 15 | 70.3 ± 7.36 |
| DBP, Day 10, n= 15 | 72.1 ± 6.41 |
Blood samples were collected at indicated time-points for analysis of AUC (0-tau). PK parameters were calculated by standard non-compartmental analysis.
| Hours*nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: AUC (0-tau) of GSK3640254 | 24.53 ± 26.5 |
Blood samples were collected at indicated time-points for analysis of Cmax. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Cmax of GSK3640254 | 1.411 ± 26.4 |
Blood samples were collected at indicated time-points for analysis of Ctau. PK parameters were calculated by standard non-compartmental analysis.
| Nanogram per milliliter | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Ctau of GSK3640254 | 0.7883 ± 30.3 |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
| Hours | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Time of Maximum Observed Concentration (Tmax) of GSK3640254 | 5.000 (2.50 to 8.00) |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
| Hours | TAF/FTC |
|---|---|
| Period 1: Tmax of TAF | 1.00 (0.50 to 2.00) |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
| Hours | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Tmax of TAF | 1.000 (0.50 to 2.00) |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
| Hours | TAF/FTC |
|---|---|
| Period 1: Tmax of FTC | 1.500 (1.00 to 3.00) |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
| Hours | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Tmax of FTC | 1.500 (1.00 to 3.08) |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
| Hours | TAF/FTC |
|---|---|
| Period 1: Tmax of TFV | 3.000 (1.50 to 4.00) |
Blood samples were collected at indicated time-points for analysis of Tmax. PK parameters were calculated by standard non-compartmental analysis.
| Hours | TAF/FTC+GSK3640254 |
|---|---|
| Period 2: Tmax of TFV | 3.000 (1.00 to 5.00) |
Collected over Non-serious AEs and SAEs were collected from the start of the study treatment up to Day 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAF/FTC | 0/16 (0%) | 0/16 (0%) | 9/16 (56.3%) |
| TAF/FTC+GSK3640254 | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Event | TAF/FTC | TAF/FTC+GSK3640254 |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/16 | 0/16 |
| Rash pustularInfections and infestations | 2/16 | 0/16 |
| NauseaGastrointestinal disorders | 2/16 | 0/16 |
| ConjunctivitisInfections and infestations | 1/16 | 0/16 |
| Abdominal discomfortGastrointestinal disorders | 1/16 | 0/16 |
| VomitingGastrointestinal disorders | 1/16 | 0/16 |
| Back painMusculoskeletal and connective tissue disorders | 1/16 | 0/16 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 1/16 | 0/16 |
| HeadacheNervous system disorders | 1/16 | 0/16 |
| SomnolenceNervous system disorders | 0/16 | 1/16 |
| Age, Continuous(Years) | TAF/FTC Followed by TAF/FTC+GSK3640254 |
|---|---|
| Mean | 33.9 ± 9.67 |
| Sex: Female, Male(Participants) | TAF/FTC Followed by TAF/FTC+GSK3640254 |
|---|---|
| Female | 0 |
| Male | 16 |
| Race/Ethnicity, Customized(Participants) | TAF/FTC Followed by TAF/FTC+GSK3640254 |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian: East Asian Heritage | 1 |
| Black or African American | 7 |
| Native Hawaiian or other pacific islander | 1 |
| White:White/Caucasian/European Heritage | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Feb 2019 to primary completion in Mar 2019, 1 month.
Results were first posted in Apr 2020, 1 year after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 1 month is below that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tenofovir alafenamide · Emtricitabine · GSK3640254